A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.

Abstract:

AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis and/or asthma. MATERIALS & METHODS:The effectiveness of the product was assessed by nasal provocation test measuring peak nasal inspiratory flow/symptoms, in vitro immunologic changes (IgE, IgG4 and IL-10) and Treatment Satisfaction Questionnaire for Medication. RESULTS:No adverse events were reported during dosing schedules. Significant decreases in symptom scores and drop of peak nasal inspiratory flow in follow-up visits (4 weeks and 1 year) were recorded. Significant increases in IgG4-specific antibody titers and IL-10 were exhibited. CONCLUSION:Significant decreases in clinical symptoms and immunological parameters were observed, accompanying a high level of patient satisfaction and tolerance.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

doi

10.2217/imt-2016-0068

subject

Has Abstract

pub_date

2016-10-01 00:00:00

pages

1169-74

issue

10

eissn

1750-743X

issn

1750-7448

journal_volume

8

pub_type

杂志文章
  • Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

    abstract::Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.11

    authors: Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

    更新日期:2014-01-01 00:00:00

  • Adoptive T-cell transfer in melanoma.

    abstract::Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.143

    authors: Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

    更新日期:2013-01-01 00:00:00

  • Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.

    abstract::Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.33

    authors: Bork K

    更新日期:2014-01-01 00:00:00

  • Antibody-targeted nanoparticles for cancer therapy.

    abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.5

    authors: Fay F,Scott CJ

    更新日期:2011-03-01 00:00:00

  • The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

    abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0029

    authors: Kourie HR,Awada G,Awada A

    更新日期:2017-06-01 00:00:00

  • EBV and nasopharyngeal carcinoma: a target for cellular therapies.

    abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.68

    authors: Smith C

    更新日期:2013-08-01 00:00:00

  • Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis.

    abstract::A 63-year-old female presented with cholestatic liver function tests in November 2016. Screening tests were negative for other causes and liver biopsy revealed primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) overlap. Ursodeoxycholic acid and azathioprine was initiated. In September 2018 she was diagn...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0184

    authors: Bhave P,Pham A,Gordon A,Moore M

    更新日期:2020-05-01 00:00:00

  • Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients.

    abstract::Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.135

    authors: Gandhi M,Jones K

    更新日期:2011-12-01 00:00:00

  • Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

    abstract::Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.85

    authors: van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

    更新日期:2010-01-01 00:00:00

  • Checkpoint inhibition in meningiomas.

    abstract::Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0017

    authors: Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

    更新日期:2016-06-01 00:00:00

  • Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis.

    abstract::Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortal time bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2 January 2020. Studies reporting the impact of IrAE on outcome in patients treated...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0179

    authors: Dall'Olio FG,Rizzo A,Mollica V,Massucci M,Maggio I,Massari F

    更新日期:2021-02-01 00:00:00

  • An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.

    abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0235

    authors: Filgueira LM,Cervantes JB,Lovelle OA,Herrera C,Figueredo C,Caballero JA,Sánchez N,Berrio J,Lorenzo G,Cepeda M,Ramos M,Saavedra D,Añe-Kouri AL,Mazorra Z,Leon K,Crombet T,Caballero A

    更新日期:2021-03-01 00:00:00

  • The role of the microbiome in childhood asthma.

    abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0048

    authors: Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

    更新日期:2017-11-01 00:00:00

  • Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity.

    abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.75

    authors: Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

    更新日期:2012-08-01 00:00:00

  • Designing effective vaccines for colorectal cancer.

    abstract::Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.61

    authors: Patel SP,Osada T,Lyerly HK,Morse MA

    更新日期:2014-01-01 00:00:00

  • Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.

    abstract::Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0178

    authors: Sacco KA,Abraham RS

    更新日期:2018-06-01 00:00:00

  • PLAC1 immunization does not induce infertility in mice.

    abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0019

    authors: Liso A,Massenzio F,Stracci F

    更新日期:2017-05-01 00:00:00

  • Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

    abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0165

    authors: da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

    更新日期:2018-08-01 00:00:00

  • Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.

    abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2019-0191

    authors: Boyle JV,Lam K,Han JK

    更新日期:2020-02-01 00:00:00

  • Conference scene: progress with promising human antibodies.

    abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.5

    authors: Larrick JW

    更新日期:2012-03-01 00:00:00

  • Adjuvant immunotherapies as a novel approach to bacterial infections.

    abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.17

    authors: Helbig ET,Opitz B,Sander LE

    更新日期:2013-04-01 00:00:00

  • What is the role of antigen-processing mechanisms in autologous tolerogenic dendritic cell therapy in organ transplantation?

    abstract::Injection of autologous tolerogenic dendritic cells is a promising strategy to diminish the burden of harmful immunosuppression in clinical transplantation. We discuss the immunoregulatory mechanisms triggered by this approach. Tolerogenic dendritic cells have long been associated with decreased antigen-processing cap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.40

    authors: Hill M,Segovia M,Cuturi MC

    更新日期:2011-04-01 00:00:00

  • PROSTVAC® targeted immunotherapy candidate for prostate cancer.

    abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.176

    authors: Shore ND

    更新日期:2014-01-01 00:00:00

  • Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

    abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0027

    authors: Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

    更新日期:2017-08-01 00:00:00

  • CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.

    abstract::Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0056

    authors: McGinnis GJ,Raber J

    更新日期:2017-09-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00

  • Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity.

    abstract::Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.12.116

    authors: Morita R,Hirohashi Y,Sato N

    更新日期:2012-11-01 00:00:00

  • Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma.

    abstract::Bacillus Calmette-Guérin and other mycobacterial vaccines are important therapeutic methods in a series of chronic inflammatory disorders characterized by Th1/Th2 imbalance in which Th2 type cells and cytokines often increase. However, few studies have investigated whether it can reduce or prevent the symptoms and att...

    journal_title:Immunotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/imt.12.156

    authors: Ming M,Li C,Luo Z,Lv S

    更新日期:2013-02-01 00:00:00

  • Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

    abstract:AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.14.40

    authors: Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

    更新日期:2014-01-01 00:00:00

  • Immunotherapy for food allergies: a myth or a reality?

    abstract::Food allergy is a worldwide issue, with an estimated prevalence of 2-10%. An effective treatment is not available for people affected and the only management is the avoidance of the allergen. Oral immunotherapy and sublingual immunotherapy have been tested by several authors, in particular for milk, egg and peanuts al...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.115

    authors: Praticò AD,Leonardi S

    更新日期:2015-01-01 00:00:00